C4 Therapeutics (CCCC) Interest & Investment Income (2020 - 2026)

C4 Therapeutics' Interest & Investment Income history runs 7 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 6.54% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $10.2 million (down 24.23% YoY), while the FY2025 annual figure was $10.3 million, down 28.28% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $2.7 million, down from $2.8 million in the prior quarter.
• The five-year high for Interest & Investment Income was $3.9 million in Q1 2024, with the low at $276000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $2.6 million (2023), against an average of $2.4 million.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income soared 1156.62% in 2022, then plunged 37.23% in 2025.
• C4 Therapeutics' Interest & Investment Income stood at $1.7 million in 2022, then soared by 72.62% to $2.9 million in 2023, then grew by 10.75% to $3.3 million in 2024, then slipped by 14.91% to $2.8 million in 2025, then declined by 4.46% to $2.7 million in 2026.
• Business Quant data shows CCCC's Interest & Investment Income at $2.7 million in Q1 2026, $2.8 million in Q4 2025, and $2.2 million in Q3 2025.